Literature DB >> 22976593

Anterior cruciate ligament reconstruction with the ligament augmentation and reconstruction system: a systematic review.

Simon D S Newman1, Henry D E Atkinson, Charles A Willis-Owen.   

Abstract

PURPOSE: The Ligament Augmentation and Reconstruction System (LARS) is a third generation of synthetic ligament, designed to overcome the issues of graft failure and synovitis which led previous generations of synthetic ligaments to fall out of favour. The theoretical benefits of LARS are appealing but this has not led to widespread uptake of the system in preference to autograft. The aim of this systematic review is to assess whether the evidence exists to support the use of LARS with respect to outcomes and complications.
METHODS: A systematic search process was undertaken from January 1990 to June 2012 to identify primary evidence relating to the use of LARS in anterior cruciate ligament (ACL) single ligament reconstruction.
RESULTS: Nine studies were found meeting the search criteria including a single randomised controlled trial, two comparative series and six further observational case series. Overall the methodological quality of the studies was poor with follow-up to a maximum of five years. Reported outcome scores were good for LARS and comparable to autograft techniques. Complication rates were low and comparable to those published for autograft techniques within the wider literature. Two reported incidences of synovitis were identified in case reports.
CONCLUSIONS: The current literature supports the use of LARS in the short to medium term. However, high-quality studies with long-term follow-up are required to determine whether the use of LARS is preferable to autograft for ACL reconstruction over the longer term. Synovitis appears to be a rare complication closely related to imperfect graft positioning.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22976593      PMCID: PMC3560896          DOI: 10.1007/s00264-012-1654-y

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  20 in total

1.  A new generation of artificial ligaments in reconstruction of the anterior cruciate ligament. Two-year follow-up of a randomised trial.

Authors:  T Nau; P Lavoie; N Duval
Journal:  J Bone Joint Surg Br       Date:  2002-04

2.  Disabling synovitis associated with LARS artificial ligament use in anterior cruciate ligament reconstruction: a case report.

Authors:  Constantine M Glezos; Alison Waller; Henry E Bourke; Lucy J Salmon; Leo A Pinczewski
Journal:  Am J Sports Med       Date:  2012-03-09       Impact factor: 6.202

3.  Four-strand hamstring tendon autograft versus LARS artificial ligament for anterior cruciate ligament reconstruction.

Authors:  Zhong-tang Liu; Xian-long Zhang; Yao Jiang; Bing-Fang Zeng
Journal:  Int Orthop       Date:  2009-04-25       Impact factor: 3.075

4.  [Comparison between four-strand semitendinosus tendon autograft and ligament advanced reinforcement system for anterior cruciate ligament reconstruction by arthroscopy].

Authors:  Qinbo Fan; Jifeng Fan
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2008-06

5.  No difference in knee function or prevalence of osteoarthritis after reconstruction of the anterior cruciate ligament with 4-strand hamstring autograft versus patellar tendon-bone autograft: a randomized study with 10-year follow-up.

Authors:  Inger Holm; Britt Elin Oiestad; May Arna Risberg; Arne Kristian Aune
Journal:  Am J Sports Med       Date:  2010-01-23       Impact factor: 6.202

6.  The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.

Authors:  S H Downs; N Black
Journal:  J Epidemiol Community Health       Date:  1998-06       Impact factor: 3.710

Review 7.  Ipsilateral graft and contralateral ACL rupture at five years or more following ACL reconstruction: a systematic review.

Authors:  Rick W Wright; Robert A Magnussen; Warren R Dunn; Kurt P Spindler
Journal:  J Bone Joint Surg Am       Date:  2011-06-15       Impact factor: 5.284

8.  Quality of life and clinical outcome after anterior cruciate ligament reconstruction using patellar tendon graft or quadrupled semitendinosus graft: an 8-year follow-up of a randomized controlled trial.

Authors:  Björn Barenius; Martin Nordlander; Sari Ponzer; Jan Tidermark; Karl Eriksson
Journal:  Am J Sports Med       Date:  2010-06-21       Impact factor: 6.202

9.  Patient satisfaction needs as related to knee stability and objective findings after ACL reconstruction using the LARS artificial ligament.

Authors: 
Journal:  Knee       Date:  2000-07-01       Impact factor: 2.199

10.  Synthetic grafts for anterior cruciate ligament rupture: 19-year outcome study.

Authors:  Alberto Ventura; Clara Terzaghi; Claudio Legnani; Enrico Borgo; Walter Albisetti
Journal:  Knee       Date:  2009-08-31       Impact factor: 2.199

View more
  24 in total

1.  Long-term results of a randomized study on anterior cruciate ligament reconstruction with or without a synthetic degradable augmentation device to support the autograft.

Authors:  Lars Peterson; Ulf Eklund; Björn Engström; Magnus Forssblad; Tönu Saartok; Anders Valentin
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-08-31       Impact factor: 4.342

2.  Anterior cruciate ligament reconstruction with LARS™ artificial ligament results at a mean follow-up of eight years.

Authors:  Paolo Domenico Parchi; Ciapini Gianluca; Lorenzo Dolfi; Alessandro Baluganti; Piolanti Nicola; Fabio Chiellini; Michele Lisanti
Journal:  Int Orthop       Date:  2013-06-29       Impact factor: 3.075

3.  Biological and Biomechanical Evaluation of Autologous Tendon Combined with Ligament Advanced Reinforcement System Artificial Ligament in a Rabbit Model of Anterior Cruciate Ligament Reconstruction.

Authors:  Xin-Min Wang; Gang Ji; Xiao-Meng Wang; Hui-Jun Kang; Fei Wang
Journal:  Orthop Surg       Date:  2018-04-06       Impact factor: 2.071

4.  Biomechanical evaluation of four femoral fixation configurations in a simulated anterior cruciate ligament replacement using a new generation of Ligament Advanced Reinforcement System (LARS™ AC).

Authors:  Olivier Barbier; Sandra Guérard; Philippe Boisrenoult; Patricia Thoreux
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-01-30

5.  Three intrasubstance failures of a LARS™ ligament used for ligament reconstruction.

Authors:  V Ramsingh; A D Yewlett; H C Pullen
Journal:  Ann R Coll Surg Engl       Date:  2019-01-03       Impact factor: 1.891

6.  The knee joint in sports medicine.

Authors:  Albert van Kampen
Journal:  Int Orthop       Date:  2013-01-11       Impact factor: 3.075

7.  The biomechanics of biodegradable versus titanium interference screw fixation for anterior cruciate ligament augmentation and reconstruction.

Authors:  Max Ettinger; Diana Schumacher; Tilman Calliess; Antonios Dratzidis; Marco Ezechieli; Christof Hurschler; Christoph Becher
Journal:  Int Orthop       Date:  2014-08-15       Impact factor: 3.075

8.  A quicker degradation rate is yielded by a novel kind of transgenic silk fibroin consisting of shortened silk fibroin heavy chains fused with matrix metalloproteinase cleavage sites.

Authors:  Guoping Huang; Danfeng Yang; Chunfeng Sun; Jianping Huang; Keping Chen; Chunxia Zhang; Huiqing Chen; Qin Yao
Journal:  J Mater Sci Mater Med       Date:  2014-05-07       Impact factor: 3.896

9.  Primary ACL reconstruction using the LARS device is associated with a high failure rate at minimum of 6-year follow-up.

Authors:  Scott John Tulloch; Brian Meldan Devitt; Tabitha Porter; Taylor Hartwig; Haydn Klemm; Sam Hookway; Cameron John Norsworthy
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2019-03-22       Impact factor: 4.342

Review 10.  Scaffolds for tendon and ligament repair and regeneration.

Authors:  Anthony Ratcliffe; David L Butler; Nathaniel A Dyment; Paul J Cagle; Christopher S Proctor; Seena S Ratcliffe; Evan L Flatow
Journal:  Ann Biomed Eng       Date:  2015-02-04       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.